Detalhe da pesquisa
1.
Observational, Multicenter Study on the Efficacy, Tolerability, and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis Older than 80 Years.
Respiration
; 102(1): 25-33, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36366821
2.
Long-term prognostic outcomes in patients with haemoptysis.
Respir Res
; 22(1): 219, 2021 Aug 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34348724
3.
Do We Really Need to Treat Over-80-Year-Old Patients Affected by IPF? A Response.
Respiration
; 102(7): 526-527, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37379825
4.
Observational, multicentre study on the epidemiology of haemoptysis.
Eur Respir J
; 51(1)2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29301924
5.
Predictors of Stability/Improvement of Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis After One Year of Treatment With Nintedanib.
Arch Bronconeumol
; 59(7): 464-466, 2023 07.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-36894471
6.
Predictors of Malignancy in Patients With Haemoptysis.
Arch Bronconeumol
; 58(8): 618-620, 2022 08.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-35312538
7.
Type 3 deiodinase and consumptive hypothyroidism: a common mechanism for a rare disease.
Front Endocrinol (Lausanne)
; 4: 115, 2013 Sep 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-24027558